King Pharmaceuticals KG Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | —— | —— | —— | ||
| $15.83M+24.9% | $12.67M+36.9% | $9.26M+282% | $2.42M— | $0— | ||
| $43.4M+27.5% | $34.05M+35.9% | $25.06M+199% | $8.37M+143% | $3.44M-10.5% | ||
| $39.66M+36.5% | $29.06M+60.3% | $18.13M+113% | $8.53M+84.3% | $4.63M-9.4% | ||
| $23K-4.2% | $24K+200% | -$24K— | $0— | —— | ||
| $8.3M+19.2% | $6.96M+6.2% | $6.55M+519% | $1.06M— | $0— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $132K+5.6% | $125K+2.5% | $122K+307% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$5,000.550.0% | -$5,000.49-600% | $1,000.000.0% | $1,000.00— | $0.00— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| 25.9M+24.0% | 20.9M+16.7% | 17.9M+38.7% | 12.9M+17.1% | 11M— | ||
| 25.9M+24.0% | 20.9M+16.7% | 17.9M+38.7% | 12.9M+17.1% | 11M— | ||
| $6.97M+7.8% | $6.46M+51.5% | $4.27M+222% | $1.33M— | $0— | ||
| $8.75M+43.6% | $6.09M+25.4% | $4.86M+343% | $1.1M— | $0— | ||
| $8.86M+42.7% | $6.21M+24.4% | $4.99M+356% | $1.1M— | $0— | ||
| $11.25M+25.1% | $8.99M+102% | $4.45M+175% | -$5.96M— | $0— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$0.49-14.0% | -$0.43-87.0% | -$0.23-109% | -$0.11— | $0— | ||
| —— | —— | —— | —— | —— | ||
| -$3.63M-23.1% | -$2.95M-52.6% | -$1.93M-63.1% | -$1.19M— | —— | ||
| $4.6M+47.0% | $3.13M+48.2% | $2.11M+436% | $394K— | $0— | ||
| $272K-3.2% | $281K+368% | $60K-97.9% | $2.89M— | —— | ||
| $8.39M+38.1% | $6.08M+46.4% | $4.15M+28.5% | $3.23M-1.0% | $3.26M-10.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$12.93M+31.0% | -$18.74M-160% | $31.42M+310% | $7.67M+639% | -$1.42M+9.4% | ||
| -$71.02M-30.8% | -$54.28M-14.9% | -$47.25M-88.3% | -$25.09M— | —— | ||
| —— | —— | —— | —— | -$828.75K+43.4% | ||
| $13.76M+39.5% | $9.87M+74.7% | $5.65M+272% | $1.52M— | —— | ||
| $10.89M+30.5% | $8.34M+63.5% | $5.1M+207% | $1.66M+807% | $183K-14.1% | ||
| —— | —— | —— | -$40M— | —— | ||
| $199.94M+36.1% | $146.95M+40.7% | $104.41M+18.2% | $88.33M— | —— | ||
| -$110.4M-14.8% | -$96.14M-214% | -$30.65M-43.0% | -$21.44M— | —— | ||
| -$106.77M-14.6% | -$93.19M-225% | -$28.72M-41.8% | -$20.25M— | —— | ||
| $28K+33.3% | $21K+16.7% | $18K+1,700% | $1K— | —— | ||
| $1.55M+44.1% | $1.08M+78.0% | $604K+23.3% | $490K— | —— | ||
| $8.86M+42.7% | $6.21M+24.4% | $4.99M+356% | $1.1M— | $0— | ||
| $4.19M+41.7% | $2.95M+177% | $1.07M+655% | $141K— | —— | ||
| $100.91M+60.7% | $62.79M+313% | $15.19M+108% | $7.31M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is King Pharmaceuticals's revenue?
- King Pharmaceuticals (KG) generated $43.4M in revenue over the trailing twelve months, up 1160.2% year over year.
- Is King Pharmaceuticals profitable?
- King Pharmaceuticals reported $57.0M in net income over the trailing twelve months, a 131.4% net margin.
- What is King Pharmaceuticals's earnings per share?
- King Pharmaceuticals's diluted EPS over the trailing twelve months is $13.30.
- Where does King Pharmaceuticals's income statement data come from?
- Every line is extracted from King Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
